ACHC vs UHS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: UHS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACHC and UHS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACHC and UHS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Acadia Healthcare (NASDAQ: ACHC) is the leading pure-play behavioral healthcare provider in the United States, operating roughly 277 facilities with more than 12,500 licensed beds across about 40 states and Puerto Rico as of the end of 2025. Its business spans four service lines: acute inpatient psychiatric hospitals (its largest and fastest-growing segment), specialty treatment facilities, comprehensive treatment centers for opioid-use disorder, and residential treatment centers. Revenue is heavily tied to government payors, with Medicaid at roughly 58 percent, commercial at about 25 percent, and Medicare near 14 percent, and no single facility contributing more than about 4 percent of total revenue.

Full ACHC guide

Universal Health Services is a Pennsylvania-based healthcare company that owns and operates acute care hospitals, behavioral health facilities, outpatient centers, and ambulatory surgery locations across the United States and in the United Kingdom. Its two core segments are acute care, which covers general hospitals and emergency and surgical services, and behavioral health, which spans inpatient psychiatric and addiction treatment facilities where UHS is one of the largest operators in the country. The company also expanded its virtual behavioral health reach through the acquisition of Talkspace.

Full UHS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ACHC drivers: Structural demand for behavioral health; Bed expansion and de novo growth.
• UHS drivers: Behavioral health scale; Acute care volumes and pricing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Legal and regulatory exposure is the defining risk. For UHS, the largest risks are tied to government reimbursement.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ACHC if you believe its drivers more; UHS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACHC and UHS guides.

ACHC. Acadia trades around $30 per share after a volatile year that saw the stock swing from roughly $11 to $33, reflecting litigation and guidance concerns. On a low-single-digit forward EBITDA multiple and mid-teens forward P/E against its guidance, the market is pricing meaningful legal and reimbursement uncertainty. Reported earnings remain depressed by legal and interest costs even as adjusted metrics grow.

UHS. UHS trades at a notably low price-to-earnings multiple, in the high single digits, well below broader market averages and its own longer-run history. That reflects investor caution around reimbursement and policy exposure rather than weak results, since revenue grew about 9.7 percent in 2025 and momentum carried into 2026.

Headline figures (approximate, July 2026): ACHC shows revenue (2025) ~$3.31B, 2026 revenue guidance ~$3.37B to $3.45B, 2026 adj. ebitda guidance ~$580M to $615M, 2026 adj. eps guidance ~$1.35 to $1.60; UHS shows revenue (fy2025) ~$17.4B, net income attributable to uhs (fy2025) ~$1.49B, diluted eps (fy2025) ~$23.10, market cap ~$10B.

ACHC and UHS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ACHC and UHS exposure against your real portfolio. It is not an investment adviser.